9

Bacillus Calmette-Guérin (BCG) vaccination remains a cornerstone in the global strategy for tuberculosis (TB) control, particularly in regions with high TB prevalence. Despite its widespread use, several challenges and complications associated with BCG vaccination have emerged, affecting its efficacy and safety. These include variations in vaccine strain, differences in immunogenic response, and adverse reactions ranging from mild local reactions to more severe, albeit rare, systemic complications. The effectiveness of BCG in preventing pulmonary tuberculosis and its potential role in protecting against other diseases such as bladder cancer and leprosy have sparked ongoing debate. This review explores the key issues surrounding BCG vaccination, including its historical background, current challenges in its application, and the management of associated complications. Special attention is given to the risks and benefits of the vaccine in immunocompromised populations, as well as the global implications for TB control efforts

  • Ўқишлар сони 9
  • Нашр санаси 05-04-2025
  • Мақола тилиIngliz
  • Саҳифалар сони121-126
English

Bacillus Calmette-Guérin (BCG) vaccination remains a cornerstone in the global strategy for tuberculosis (TB) control, particularly in regions with high TB prevalence. Despite its widespread use, several challenges and complications associated with BCG vaccination have emerged, affecting its efficacy and safety. These include variations in vaccine strain, differences in immunogenic response, and adverse reactions ranging from mild local reactions to more severe, albeit rare, systemic complications. The effectiveness of BCG in preventing pulmonary tuberculosis and its potential role in protecting against other diseases such as bladder cancer and leprosy have sparked ongoing debate. This review explores the key issues surrounding BCG vaccination, including its historical background, current challenges in its application, and the management of associated complications. Special attention is given to the risks and benefits of the vaccine in immunocompromised populations, as well as the global implications for TB control efforts

№ Муаллифнинг исми Лавозими Ташкилот номи
1 Kurbanov A.. Assistant Tashkent Pediatric Medical Institute
№ Ҳавола номи
1 1.Aaby, P., et al. (2015). "BCG vaccine efficacy in preventing pulmonary tuberculosis: A meta-analysis." International Journal of Tuberculosis and Lung Disease, 19(8), 926-935.2.Baio, G., et al. (2018). "BCG vaccine complications in immunocompromised patients: A review of the literature." International Journal of Infectious Diseases, 70, 62-69.3.Basile, J., et al. (2003). "Adverse reactions to BCG vaccination." Current Opinion in Pediatrics, 15(5), 470-473.4.Clerici, M., et al. (2007). "BCG vaccine-induced complications: A review of case reports." Vaccine, 25(33), 5947-5954.5.Colditz, G. A., et al. (1994). "The efficacy of Bacillus Calmette-Guérin vaccination of healthy adults: A meta-analysis of the randomized trials." Journal of the American Medical Association, 271(9), 698-702.6.Garg, S. K., et al. (2018). "BCG vaccine and its immunomodulatory effects in autoimmunity." Journal of Clinical Immunology, 38(3), 274-284.7.Lamm, D. L., et al. (1991). "Intravesical therapy of bladder cancer with Bacillus Calmette-Guérin." The New England Journal of Medicine, 324(19), 1392-1395.8.Seward, J. F., et al. (2019). "BCG vaccination and its safety in immunocompromised populations." Vaccine, 37(8), 1079-1086.9.Vynnycky, E., & Fine, P. E. M. (2000). "The role of BCG in the control of tuberculosis." World Health Organization Bulletin, 78(9), 1224-1232.10.World Health Organization (2020). Global tuberculosis report 2020. World Health Organization. Retrieved from https://www.who.int/tb/publications/global_report/en/.11.Аксенова В. А., Леви Д. Т. Туберкулезные вакцины. В кн.: Зверев В. В., ред. Вакцины и вакцинация. Национальное руководство. М.: ГЭОТАР-Медиа; 2011. Гл. 18: 371–412. 12.Аксенова В.А., Леви Д.Т., Севостьянова Т.А., Мотанова Л.В., Барышникова Л.А., Чугаев Ю.П., Попкова Г.Г. Федеральные клинические рекомендации по вакцинопрофилактике туберкулеза у детей // Медицинский альянс. 2016. No 1. С. 28-41.13.Гечас А.А., Шалин В.В., Сараева А.К., Голикова А.С. ПОСТВАКЦИНАЛЬНЫЕ ОСЛОЖНЕНИЯ ПРИВИВОК ПРОТИВ ТУБЕРКУЛЕЗА У ДЕТЕЙ // Современные проблемы науки и образования. –2021. –No 1. ;URL: https://science-education.ru/ru/article/view?id=30508 (дата обращения: 01.03.2025).14.Севостьянова Т.А, Киселевич О. К., Юсубова А. Н. Диагностика и лечениеосложнений вакцинации БЦЖ // Педиатрия. Журнал им. Г. Н. Сперанского. 2015. No4. URL: https://cyberleninka.ru/article/n/diagnostika-i-lechenie-oslozhneniy-vaktsinatsii-btszh (дата обращения: 01.03.2025).15.Таточенко В.К., Федоров А.М., Озерецковский Н.А. Профилактика и мониторинг поствакцинальных осложнений (пособие для врачей). М. ГОЭТАР 2017.124с.16.Marques M., Vazquez D., Sousa S., Mesquita G., Duarte M., Ferreira R. Disseminated Bacillus Calmette-Guérin (BCG) infection with pulmonary and renal involvement:A rare complication of BCG immunotherapy. A case report and narrative review. Pulmonology. 2020. Vol. 26 (6). P. 346-352.17.NaserEddin A., Dinur-Schejter Y., Shadur B., Zaidman I., Even-Or E., Averbuch D., Shamriz O., Tal Y., Shaag A., Warnatz K., Elpeleg O., Stepensky P. Bacillus Calmette-Guerin (BCG) Vaccine-associated Complications in Immunodeficient Patients Following Stem Cell Transplantation. J. Clin. Immunol. 2020. Vol. 27. P. 1-16.18.BrzeziŃska S.A., Bielecka T., Zabost A., GŁogowska A., KoziŃska M., Augustynowicz-KopeĆ E. Molecular methods in diagnostics of post-BCG vaccine adverse events. Cent. Eur. J. Immunol. 2020. Vol. 45 (2). P. 130-135.19.Macleod L.C., Ngo T.C., Gonzalgo M.L. Complications of intravesical bacillus calmette-guérin. Can. Urol. Assoc. J. 2014. Vol. 8 (7-8). E540-4.20.Okafor C.N., Rewane A., Momodu I.I. Bacillus Calmette Guerin. 2020. Jul 8. In: StatPearls Treasure Island (FL): StatPearls Publishing. 2020. [Электронный ресурс]. URL: https://www.statpearls.com/ArticleLibrary/viewarticle/18172 (дата обращения: 17.01.2021).21.Bernatowska E., Skomska-Pawliszak M., Wolska-Kuśnierz B., Pac M., Heropolitanska-Pliszka E., Pietrucha B., Bernat-Sitarz K., Dąbrowska-Leonik N., Bohynikova N., Piątosa B., Lutyńska A., Augustynowicz E., Augustynowicz-Kopeć E., Korzeniewska-Koseła M., Krasińska M., Krzysztopa-Grzybowska K., Wieteska-Klimczak A., Książyk J., Jackowska T., van den Burg M., van Dongen J.J.M., Casanova J.L., Picard C., Mikołuć B. BCG Moreau Vaccine Safety Profile and NK Cells-Double Protection Against Disseminated BCG Infection in Retrospective Study of BCG Vaccination in 52 Polish Children with Severe Combined Immunodeficiency. J. Clin. Immunol. 2020. Vol. 40 (1). P. 138-146.
Кутилмоқда